Quick Answer
PharmaCyte Biotech, Inc. reported Cash and Equivalents of $15.17 million for fiscal year 2025.
PharmaCyte Biotech, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $15.17M | -69.8% |
| 2024 | $50.18M | -26.2% |
| 2023 | $68.04M | -20.3% |
| 2022 | $85.40M | +42749.7% |
| 2013 | $199.3K | +1167.6% |
| 2012 | $15.7K | -72.5% |
| 2011 | $57.2K | +7889.0% |
| 2010 | $716.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| January 31, 2026 | $20.17M | +23.1% | +30.9% |
| October 31, 2025 | $15.41M | -26.1% | +16.9% |
| July 31, 2025 | $13.18M | -59.6% | -13.1% |
| April 30, 2025 | $15.17M | -69.8% | -7.4% |
| January 31, 2025 | $16.38M | -73.2% | -21.4% |
| October 31, 2024 | $20.84M | -71.6% | -36.1% |
| July 31, 2024 | $32.64M | -56.3% | -35.0% |
| April 30, 2024 | $50.18M | -26.2% | -18.0% |
- PharmaCyte Biotech, Inc. showed a decrease of -69.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2010–2025 period, PharmaCyte Biotech, Inc.’s cash and equivalents has grown by 2118917.2% (from $716.00 to $15.17 million).
- The most recent figure is from PharmaCyte Biotech, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on August 11, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: